Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices 65183 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: October 27, 2023. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G13A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mairi Noverr, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activitie, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G13A, Rockville, MD 

20852, (240) 747–7530, mairi.noverr@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 15, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20421 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing and 

Collaboration 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention described 

below presents an advancement 

concerning osteoclast fusion; osteoclasts 

are responsible for human skeletal 

remodeling and their dysfunction is a 

key factor for both rare and common 

bone diseases. The invention covers 

methods for modulating osteoclast 

fusion and bone resorption through the 

Lupus autoantigen (La) protein. The 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development (NICHD), National 

Institutes of Health, has conducted 

conceptual in-vitro studies and is now 

seeking potential licensees and 

collaborators for further development 

and advancement. 

ADDRESSES: Inquiries relating to this 

licensing and collaboration opportunity 

should be directed to: Heather Gunas, 

JD, MPH, Senior Technology Transfer 

Manager, National Cancer Institute 

(NCI) Technology Transfer Center, 9609 

Medical Center Drive, Room 1E446, 

Rockville, MD 20850 (for overnight 

mail) or Bethesda, MD 20892 (for 

regular mail), Telephone: (240) 276– 

5530; Facsimile: (240) 276–5504; Email: 

gunash@mail.nih.gov. A Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished 

information regarding this invention. 

SUPPLEMENTARY INFORMATION: The 

following and all continuing U.S. and 

foreign patents/patent applications 

thereof are available for licensing: PCT 

Application No. PCT/US22/018639, 

filed March 3, 2022, and entitled ‘‘La 

protein as a novel regulator of 

osteoclastogenesis.’’ The Lupus 

autoantigen (La) protein is a master 

regulator of osteoclasts. The technology 

involves a novel mechanism for precise 

regulation of osteoclastogenesis through 

the manipulation of surface La protein. 

The ability of osteoclasts to remodel 

bone can be modulated by: (1) 

administering an effective amount of La 

protein or (2) administering an agent 

that modulates La protein expression or 

activity. Current solutions for bone 

diseases are usually broad-spectrum 

treatments that either coat the skeletal 

system or inhibit osteoclast 

development and these approaches can 

result in off-target side effects. This 

technology’s approach to regulating 

osteoclast fusion and osteoclastogenesis 

by targeting the La protein should 

bypass many side effects. The 

technology has been supported by 

conceptual in-vitro data and lead 

optimization is ongoing; further 

research and development are required 

to advance it towards disease-specific 

preclinical and clinical stages. 

Potential Commercial Application: 

Treatment of common and rare bone 

diseases, including osteoporosis, Paget’s 

disease of bone, fibrous dysplasia, 

rheumatoid arthritis, osteopetrosis, 

osteomyelitis, or metastatic bone 

disease. 

Development Stage: In-vitro study 

completed and lead optimization 

ongoing. 

Dated: September 18, 2023. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2023–20479 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Social and Environmental Determinants of 

Health Study Section. 

Date: October 18–19, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ananya Paria, DHSC, 

MPH, MS, Scientific Review Officer, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1007H, 

Bethesda, MD 20892, (301) 827–6513, 

pariaa@mail.nih.gov. 

Name of Committee: Digestive, Kidney and 

Urological Systems Integrated Review Group; 

Digestive and Nutrient Physiology and 

Diseases Study Section. 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aster Juan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20817, 301–435–5000, juana2@mail.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Human 

Studies of Diabetes and Obesity Study 

Section. 

Date: October 19–20, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Hui Chen, MD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 


ddrumheller on DSK120RN23PROD with NOTICES1
65184 Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices 

Drive, Room 6164, Bethesda, MD 20892, 

(301) 435–1044, chenhui@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 15, 2023. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20437 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; K99–U24–R13 SEP. 

Date: November 3, 2023. 

Time: 2:30 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sarah Jo Wheelan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8823, wheelansj@nih.gov. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel SEP–1 K99 HG013541–01 Member 

Conflict. 

Date: November 3, 2023. 

Time: 6:15 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sarah Jo Wheelan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8823, wheelansj@nih.gov. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Diversity Centers. 

Date: November 16, 2023. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rudy O. Pozzatti, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8739, pozzattr@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: September 18, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20490 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, And Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Mentored Transition to Independence Study 

Section. 

Date: November 16–17, 2023. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Canopy by Hilton, Washington, 

DC, Bethesda North, 940 Rose Avenue, North 

Bethesda, MD 20892 (Hybrid Meeting). 

Contact Person: Giuseppe Pintucci, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 205–H, 

Bethesda, MD 20892, (301) 827–7969, 

Pintuccig@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 18, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20492 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Diabetes Mellitus Interagency 

Coordinating Committee Meeting 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Diabetes Mellitus 

Interagency Coordinating Committee 

(DMICC) will hold a meeting on 

November 16, 2023. The topic for this 

meeting will be ‘‘The Application of 

Digital Health Technology to Type 2 

Diabetes Management: Current Status, 

Research Gaps, and Opportunities’’. The 

meeting is open to the public. 

DATES: The meeting will be held on 

November 16, 2023 from 12:00 p.m. to 

4:00 p.m. EST. 

ADDRESSES: The meeting will be held 

via the Zoom online video conferencing 

platform. For details, and to register, 

please contact dmicc@mail.nih.gov. 

FOR FURTHER INFORMATION CONTACT: For 

further information concerning this 

meeting, including a draft agenda, 

which will be posted when available, 

see the DMICC website, 

www.diabetescommittee.gov, or contact 

Dr. William Cefalu, Executive Secretary 

of the Diabetes Mellitus Interagency 

Coordinating Committee, National 

Institute of Diabetes and Digestive and 

Kidney Diseases, 6707 Democracy 

Boulevard, Democracy 2, Room 6037, 

Bethesda, MD 20892, telephone: 301– 

435–1011; email: dmicc@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 42 U.S. Code 285c–3, 

the DMICC, chaired by the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK) comprising 

members of the Department of Health 

and Human Services and other federal 

agencies that support diabetes-related 


ddrumheller on DSK120RN23PROD with NOTICES1